Latest DNA vaccination Stories

BLUE BELL, Pa., May 9, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) today reported financial results for the quarter ended March 31, 2012. Total revenue was $1.7 million for the three months ended March 31, 2012, compared to $3.1 million for the same period in 2011. Total operating expenses were $5.9 million compared to $7.5 million. The net loss attributable to common stockholders was $8.3 million, or $0.06 per share, compared to $2.4 million, or $0.02 per...

LANCASTER, Pa. and ROCKVILLE, Md., May 3, 2012 /PRNewswire/ -- Immunomic Therapeutics, Inc., ("ITI," Lancaster, PA) a privately-held biotechnology company with laboratories in Rockville, MD, announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug Application ("IND") filed for the allergy immunotherapy, JRC- LAMP-vax((TM)). On April 12th, the FDA notified ITI that there will be no clinical hold and that ITI may now...

BLUE BELL, Pa., April 2, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today it has received a U.S. Department of Defense Small Business Innovation Research Grant to advance the development of a low-cost, non-invasive surface electroporation (EP) delivery device and test its utility in combination with Inovio's novel synthetic DNA vaccines against viruses with bioterrorism potential, including hanta, puumala, arenavirus and pandemic influenza. This...

BLUE BELL, Pa., March 15, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) today reported financial results for the fourth quarter and year ended December 31, 2011. Total revenue was $1.6 million and $9.8 million for the quarter and year ended December 31, 2011, compared to $2.4 million and $6.1 million for the same periods in 2010. Total operating expenses for the quarter and year ended December 31, 2011, were $7.4 million and $31.4 million as compared to $7.6 million and...

BLUE BELL, Pa., March 13, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that it has achieved strong T cell immune responses in a Phase I clinical study of PENNVAX®-B, its product for the treatment of the HIV subtype prevalent in North America and Europe, in HIV-positive subjects. These interim results were presented by Dr. Niranjan Y. Sardesai, Inovio's Chief Operating Officer, at the Vaccine World Summit 2012 in Hyderabad, India in a...

ATLANTA, March 12, 2012 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta - based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced receipt of an "Allowed to Proceed" notice from the U.S. Food and Drug Administration (FDA) for human clinical testing of its granulocyte-macrophage colony stimulating factor (GM-CSF) -adjuvanted DNA/MVA vaccine. The Phase 1 trial is being sponsored by the National...

ATLANTA, March 7, 2012 /PRNewswire/ -- Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), a biotech company specializing in the development of HIV/AIDS vaccines, announced the results of a study suggesting that scientists may be one step closer to a vaccine that protects against multiple exposures to HIV infections. The study results were unveiled by Dr. Robinson during a presentation in Seattle at the 2012 Conference on...

BLUE BELL, Pa., March 5, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) announced today that its SynCon® therapeutic vaccine for human papillomavirus (HPV) types 6 and 11, which are associated with head & neck cancers and genital warts, among other conditions, induced strong antigen-specific CD8+ T cells in mice. This vaccine is complementary to Inovio's VGX-3100, a therapeutic vaccine targeting cervical dysplasias and cancers caused by HPV types 16 and 18,...

Very recently, researchers discovered an important population of immune cells called memory T cells living in parts of the body that are in contact with the environment (e.g., skin, lung, GI tract). How these "resident" memory T cells are generated was unknown, and their importance with regard to how our immune system remembers infection and how it prevents against re-infection is being studied intensively. Now, a study by a Brigham and Women's Hospital (BWH) research team led by Xiaodong...

Research shows for the first time that resident memory T cells prevalent in the skin are more protective in fighting infection than central memory T cells in the bloodstream TREM Rx, Inc., a biotechnology company with a proprietary technology platform for novel vaccines delivered to the skin, announced today the results of an in vivo preclinical study that shows, for the first time, that powerful cells of the immune system called TREMs (T Resident Effector Memory cells) prevalent in the...